Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Drop in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 53,938 shares, a decline of 65.7% from the February 12th total of 157,037 shares. Based on an average daily volume of 443,796 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 443,796 shares, the days-to-cover ratio is presently 0.1 days.

Oncotelic Therapeutics Price Performance

OTLC stock opened at $0.04 on Thursday. The firm has a fifty day moving average price of $0.06 and a 200 day moving average price of $0.08. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.11.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.